ImmuCell Corporation Common Stock (NASDAQ: ICCC) last traded at $10.80, up 0.09% on the session. The quote above updates while this page is open; the figures below are drawn from ImmuCell Corporation Common Stock’s own filings and are restated only when a new one is published.
ImmuCell Corporation Common Stock trades on NASDAQ under the ticker ICCC. Its market capitalisation is $98.09 million.
Valuation measures for ImmuCell Corporation Common Stock, derived from the latest quote and its most recent SEC filing.
| Market cap | $98.09M |
|---|---|
| Enterprise value | $104.48M |
| P/E ratio | 154.29 |
| Price / sales | 3.20 |
| Price / book | 3.13 |
| Beta | 0.42 |
Trailing-twelve-month figures tagged in ImmuCell Corporation Common Stock's XBRL filings with the SEC.
| Revenue (TTM) | $30.68M |
|---|---|
| Net income (TTM) | $787.4K |
| EPS (TTM) | $0.0700 |
| Gross margin | 40.32% |
| Operating margin | 12.60% |
| Return on equity | 2.51% |
| Cash | $8.86M |
Range and volume for ICCC over the past 52 weeks.
| 52-week high | $12.10 |
|---|---|
| 52-week low | $4.52 |
| Volume | 9.1K |
| Average volume | 21.1K |
| Previous close | $10.79 |
Invest a chosen dollar amount in ImmuCell Corporation Common Stock with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell ICCC.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.